CompleNAD Peptide (300 mg) SunSci Pharmaceutical

Catalogue entry: CompleNAD Peptide (300 mg) SunSci Pharmaceutical. Labelled content: 300 mg. Listed pack: 1 pen. The amount identifies labelled product content, not an administration dose.

Identity and mechanism

CompleNAD is a supplier product name, not a universally defined molecule. The name alone does not establish NAD+ identity, a particular precursor, a peptide sequence or a standardised mixture. The total labelled amount cannot reveal component quantities or the chemical form of each ingredient.

What the research measured

NAD-related human studies illustrate why this distinction matters. Grant and colleagues examined an exploratory NAD+ intervention in 2019, while Elhassan and colleagues studied nicotinamide riboside in older human muscle. These are specific substances and designs. They are not a clinical evaluation of every product with NAD in its name and do not establish the composition or efficacy of CompleNAD.

Sporting claims and limitations

Sporting promotion may link cellular energy with recovery, endurance or healthy ageing. A coenzyme's biological role does not prove the effect of an undefined formulation. MOTS-c research also cannot supply evidence for a different product merely because both are discussed under mitochondrial health. Unknown component identity and formulation create uncertainties before benefit or safety can even be compared.

Product identity and documentation

For this catalogue item, prioritise a complete ingredient specification, amounts per component, chemical forms and manufacturer traceability. A batch analysis must address the actual mixture rather than only one presumed ingredient. The selected content records the source listing without inventing a composition. Once verified documentation is available, the product can be compared with research involving the same material rather than a similar name.